VTGN VistaGen Therapeutics

VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021

VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that management will participate in the ‘Updates in Neuropsych’ panel at the virtual William Blair Biotech Focus Conference 2021 on July 15, 2021 at 9:00 a.m. PT. VistaGen will also be participating in one-on-one meetings throughout the conference.

William Blair Biotech Focus Conference 2021  

Panel:Updates in Neuropsych
Date:Thursday, July 15 at 9:00 a.m. PT
Webcast:
Registration:To attend the virtual conference, please contact your William Blair representative.

The panel will be held virtually, and a live webcast will be accessible through the page of the Investors section of the company’s website at .

About VistaGen

VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets. For more information, please visit  and connect with VistaGen on , , and .

Company Contacts

Mark A. McPartland / Mark Flather

VistaGen Therapeutics, Inc.

Phone: +1 (650) 577-3606/+1 (650) 577-3617

Email: 



EN
09/07/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on VistaGen Therapeutics

 PRESS RELEASE

Vistagen to Participate in the Maxim Group Healthcare Virtual Conferen...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in the Healthcare Virtual Conference presented by Maxim Group LLC taking place June 20 – 22, 2023 virtually on the M-Vest platform. Maxim Group Healthcare Virtual Conference 2023 Fireside Chat Date and Time: Thursday, June 22, 2023 at 1:30 p.m. Eastern T...

 PRESS RELEASE

Vistagen Announces European Patent Office Intention to Grant New PH80 ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) issued an intention to grant a patent for the treatment of migraine by nasal administration of PH80 nasal spray, one of the Company’s five rapid-onset investigational neuroactive pherine therapeutics. The patent claims also include treatment administered at the onset of migraine symptoms an...

 PRESS RELEASE

Vistagen Announces Positive Results from Exploratory Phase 2A Study of...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that PH80, one of the Company’s five investigational neuroactive nasal sprays, demonstrated statistically significant efficacy versus placebo in an exploratory Phase 2A study for the acute treatment of hot flashes (vasomotor symptoms) in women diagnosed with menopausal hot flashes. The randomized, double-blind, placebo-contro...

 PRESS RELEASE

Vistagen to Present at Jefferies 2023 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference taking place June 7 – 9, 2023 in New York City, NY. Jefferies 2023 Global Healthcare Conference Details Fireside Chat Date and Time: Friday, June 9 at 9:30 a.m. Eastern Time Location: M...

 PRESS RELEASE

Vistagen Announces Stockholder-Approved Reverse Stock Split

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that it will implement a stockholder-approved reverse stock split of its outstanding shares of common stock, at a ratio of one-for-thirty unanimously approved by its Board of Directors. Vistagen common stock will begin trading on a split-adjusted basis at the opening of trading on the Nasdaq Capital Market on Wednesday, June 7, 20...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch